J. Goldman & CO LP Viridian Therapeutics, Inc.\De Transaction History
J. Goldman & CO LP
- $3.8 Billion
- Q1 2025
A detailed history of J. Goldman & CO LP transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, J. Goldman & CO LP holds 118,594 shares of VRDN stock, worth $1.72 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
118,594
Previous 179,496
33.93%
Holding current value
$1.72 Million
Previous $3.44 Million
53.55%
% of portfolio
0.04%
Previous 0.1%
Shares
4 transactions
Others Institutions Holding VRDN
# of Institutions
189Shares Held
79.6MCall Options Held
92.2KPut Options Held
55.2K-
Deep Track Capital, LP Greenwich, CT5.38MShares$78.1 Million2.54% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$69.3 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.7MShares$68.2 Million5.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.56MShares$66.3 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$56.4 Million12.64% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $579M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...